Cell Medica

Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases that is headquartered in London, England and was founded in 2005 by Gregg Sando.

Cell Medica is also known as Kuur Therapeutics. The company looks to transforming the lives of patients with cancer and is interested in the development of off-the-shelf engineered CAR-NLT cell therapies. The company's approach includes natural biology of a subset of cytotoxic T cells, and CAR construct engineering.

The company looks to develop a growing portfolio of allogeneic CAR-NKT products to treat broad populations of patients. The goal is to harness the human immune system for the treatment of cancer. They look to license and partner through opportunities to draw on global immunotherapy expertise, and maintain their mission of harnessing the human immune system for the treatment of cancer.

Funding

Series A

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual.

Series B

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual.

Series C

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual.

Timeline

March 15, 2017

Series C funding round

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual.

November 25, 2014

Series B funding round

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual.

July 23, 2012

Series A funding round

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual.

2005

Cell Medica was founded.

People

Name
Role
LinkedIn

Gregg Sando

Founder

Further reading

Title
Author
Link
Type
Date

CAR-T player Cell Medica names Kite's European chief as CEO

Nick Paul Taylor

Web

Privately-owned UK biotech Cell Medica has named Chris Nowers its new chief executive after its founder...

The Pharma Letter

Web

T-cell immunotherapy firm Cell Medica rakes in $78M in Imperial-led series B

Nuala Moran

Web

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Evelyn Warner

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.